2020-08-24 17:45:37 - WHO

172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility


Nine CEPI-supported candidate vaccines are part of the COVAX initiative, with a further nine candidates under evaluation, and procurement conversations on-going with additional producers not currently receiving research and development (R D) funding through COVAX giving COVAX the largest and most diverse COVID-19 vaccine portfolio in the world
80 potentially self-financing countries have submitted non-binding expressions of interest to the Gavi-coordinated COVAX Facility, joining 92 low- and middle-income economies that are eligible to be supported by the COVAX Advance Market Commitment (AMC)
Goal of bringing the pandemic under control via equitable access to COVID-19 vaccines needs urgent, broadscale commitment and investment from countries172 economies are now engaged in discussions to potentially participate in COVAX, a global initiative aimed at working with vaccine manufacturers to provide countries worldwide equitable access to safe and effective vaccines, once they are licensed and approved. COVAX currently has the world s largest and most diverse COVID-19 vaccine portfolio - including nine candidate vaccines, with a further nine under evaluation and conversations underway with other COVAX, the vaccines pillar of the Access to COVID-19 Tools (ACT) Accelerator, is co-led by the Coalition for Epidemic Preparedness Innovations (CEPI), Gavi, the Vaccine Alliance, and the World Health Organization (WHO) working in partnership with developed and developing country vaccine manufacturers. It is the only global initiative that is working with governments and manufacturers to ensure COVID-19 vaccines are available worldwide to both higher-income and lower- In order to be able to secure enough doses of vaccines to protect the most vulnerable populations, such as health workers and the elderly, the next step for the partnership is to confirm potential self-financing participants intent to participate by 31 August and to turn these into binding commitments to join the COVID-19 Vaccine Global Access Facility (COVAX Facility) by 18th of September, with first upfront payments to follow thereafter, and no later than 9th of October 2020. Equal access to a COVID-19 vaccine is the key to beating the virus and paving the way for recovery from the pandemic, said Stefan L fven, Prime Minister of Sweden. This cannot be a race with a few winners, and the COVAX Facility is an important part of the solution making sure all countries can benefit from access to the world s largest portfolio of candidates and fair and equitable distribution of vaccine doses. The COVAX Facility is a Gavi-coordinated pooled procurement mechanism for new COVID-19 vaccines, through which COVAX will ensure fair and equitable access to vaccines for each participating economy, using an allocation framework currently being formulated by WHO. The COVAX Facility will do this by pooling buying power from participating economies and providing volume guarantees across a range of promising vaccine candidates, allowing those vaccine manufacturers whose expertise is essential to large scale production of the new vaccines, to make early, at-risk investments in manufacturing capacity providing participating countries and economies with the best chance at rapid access to doses of a successful COVID-19 vaccine. The success of COVAX hinges not only on countries signing up to the COVAX Facility, but also filling key funding gaps for both COVAX R D work and a mechanism to support participation of lower-income economies in the COVAX Facility. COVID-19 is an unprecedented global health challenge that can only be met with unprecedented cooperation between governments, researchers, manufacturers and multilateral partners, said Dr Tedros Adhanom Ghebreyesus, Director-General of WHO. By pooling resources and acting in solidarity through the ACT Accelerator and the COVAX Facility, we can ensure that once a vaccine is available for COVID-19, it s available equitably to all countries. CEPI is leading COVAX vaccine research and development work, which aims to develop three safe and effective vaccines which can be made available to countries participating in the COVAX Facility. Nine candidate vaccines are currently being supported by CEPI; seven of which are currently in clinical trials. Governments, vaccine manufacturers (in addition to their own R D), organizations and individuals have committed US$ 1.4 billion towards vaccine R D so far, but an additional US$1 billion is urgently needed to continue to move the portfolio forward. A further nine candidates vaccines which complement the current CEPI portfolio are currently being evaluated for inclusion in COVAX. Furthermore, COVAX will consider procuring vaccines that complement the portfolio from any producer in the conversations are already underway with a number of additional manufacturers not receiving R D support from CEPI to procure their vaccines if they are successful. Maximizing the portfolio of vaccines increases the probability of success as individual vaccines historically have a high failure rate. In the scramble for a vaccine, countries can act alone creating a few winners, and many losers - or they can come together to participate in COVAX, an initiative which is built on enlightened self-interest but also equity, leaving no country behind, said Richard Hatchett, CEO of CEPI. Only by taking a global view can we protect those most at risk around the world from the terrible effects of this disease. COVAX can deliver the vaccines that could end the pandemic, but it needs countries to step forward both to join the COVAX Facility, and also to address the serious funding shortfalls, including for R D. The decisions that are taken now about COVID-19 vaccines have the power to change our future. We must be courageous and ambitious in striving for a multilateral solution. A collaboration between Serum Institute of India (SII), Gavi and the Bill Melinda Gates Foundation announced earlier this month will ensure up to 100 million doses of AstraZeneca or Novavax s candidate vaccines, if successful, will be available to low- and middle-income economies through the COVAX Facility at just US$ 3 per dose. The arrangement also provides an option to secure additional doses if COVAX sees a need for it. Separate agreements between Gavi, CEPI and AstraZeneca, announced in June, guarantee a further 300 million doses of their candidate vaccine, if successful, for the COVAX Facility.In addition, in June Gavi launched the COVAX Advance Market Commitment (AMC), a financing instrument aimed at supporting the participation of 92 lower and middle income economies in the COVAX Facility. The COVAX AMC has raised more than US$ 600 million against an initial target of securing US$ 2 billion seed funding from sovereign donors as well as philanthropy the private sector, needed by the end of 2020. Funding the COVAX AMC will be critical to ensuring ability to pay is not a barrier to accessing COVID-19 vaccines, a situation which would leave the majority of the world unprotected, with the pandemic and its impact continuing unabated. 80 higher-income economies, which would finance the vaccines from their own public finance budgets, have so far submitted Expressions of Interest ahead of the 31 of August deadline for confirmation of intent to participate. They will partner with 92 low- and middle-income countries that will be supported by the AMC if it meets its funding targets. Together, this group of 172 countries represents more than 70% of the world s population. Among the group are representatives from every continent and more than half of the world s G20 economies. The momentum we are witnessing behind this unprecedented global effort means there could be light at the end of the tunnel: A vaccine is our best route to ending the acute phase of the pandemic and the COVAX effort is the best way to get there, said Dr Seth Berkley, CEO of Gavi, the Vaccine Alliance. For higher-income countries it represents a win-win: not only will you be guaranteed access to the world s largest portfolio of vaccines, you will also be negotiating as part of a global consortium, bringing down prices and ensuring truly global access. Signing up to the COVAX Facility gives each country its best chance at protecting the most vulnerable members of their populations which in turn gives the world its best chance at mitigating the toll this pandemic has taken on individuals, communities and the global economy. To make this end-to-end vision a reality, we need countries to make end-to-end commitments: funding R D, signing up to the Facility, and supporting the COVAX AMC. The COVAX Facility is coordinated by Gavi, the Vaccine Alliance, and forms a key part of COVAX the vaccines pillar of the ACT Accelerator, a ground-breaking global collaboration involving vaccine manufacturers to accelerate the development, production, and equitable access to COVID-19 tests, treatments, and vaccines. The overall aim of COVAX is to accelerate the development and manufacture of COVID-19 vaccines, and to guarantee fair and equitable access for every country in the world. It will achieve this by sharing the risks associated with vaccine development, and where necessary investing in manufacturing upfront so vaccines can be deployed at scale as soon as they are proven to be safe and effective, and pooling procurement and purchasing power to achieve sufficient volumes to end the acute phase of the pandemic by 2021.The goal of COVAX is by the end of 2021 to deliver two billion doses of safe, effective vaccines that have passed regulatory approval and/or WHO prequalification. These vaccines will be offered equally to all participating countries, proportional to their populations, initially prioritising healthcare workers then expanding to cover vulnerable groups, such as the elderly and those with pre-existing conditions. Further doses will then be made available based on country need, vulnerability and COVID-19 threat. The COVAX Facility will also maintain a buffer of doses for emergency and humanitarian use, including dealing with severe outbreaks before they spiral out of control. ---------------------------------------------Notes to editorsThe full list of CEPI-supported candidate vaccines is as follows:Inovio, United States of America (Phase I/II)Moderna, United States of America (Phase III)CureVac, Germany (Phase I)Institut Pasteur/Merck/Themis, France/ United States of America /Austria (Preclinical)AstraZeneca/University of Oxford, United Kingdom of Great Britain and Northern Ireland (Phase III)University of Hong Kong, China (Preclinical)Novavax, United States of America (Phase I/II)Clover Biopharmaceuticals, China (Phase I)University of Queensland/CSL, Australia (Phase I)The nine candidate vaccines that are currently being evaluated for inclusion in the COVAX Facility include two from China, two from the United States of America, one from the People s Republic of Korea, one from the United Kingdom of Great Britain and Northern Ireland and one global, multi-manufacture partnership. Two of these are in Phase I trials, two are tech transfers and the remainder are at the discovery stage.

The 80 countries that have submitted expressions of interest to the Gavi-coordinated COVAX Facility include 43 that have agreed to be publicly named: Andorra, Argentina, Armenia, Botswana, Brazil, Canada, Chile, Colombia, Croatia, Czech Republic, Dominican Republic, Estonia, Finland, Greece, Iceland, Iraq, Ireland, Israel, Japan, Jordan, Kuwait, Lebanon, Luxembourg, Mauritius, Mexico, Monaco, Montenegro, New Zealand, North Macedonia, Norway, Palau, Portugal, Qatar, the People s Republic of Korea, San Marino, Saudi Arabia, Seychelles, Singapore, South Africa, Switzerland, United Arab Emirates, United Kingdom of Great Britain and Northern Ireland and Venezuela.In July the Gavi Board agreed on the 92 economies that will be supported the COVAX Advance Market Commitment (AMC). The full list is as follows:Low income: Afghanistan, Benin, Burkina Faso, Burundi, Central African Republic, Chad, the Democratic Republic of the Congo, Eritrea, Ethiopia, Gambia, Guinea, Guinea-Bissau, Haiti, Democratic People s Republic of Korea, Liberia, Madagascar, Malawi, Mali, Mozambique, Nepal, Niger, Rwanda, Sierra Leone, Somalia, South Sudan, Syrian Arab Republic, Tajikistan, Togo, Uganda, United Republic of Tanzania and Yemen.Lower-middle income: Angola, Algeria, Bangladesh, Bhutan, Bolivia, Cabo Verde, Cambodia, Cameroon, Comoros, Congo, C te d Ivoire, Djibouti, Egypt, El Salvador, Eswatini, Ghana, Honduras, India, Indonesia, Kenya, Kiribati, Kyrgyztan, Lao People s Democratic Republic, Lesotho, Mauritania, Micronesia, Moldova, Mongolia, Morocco, Myanmar, Nicaragua, Nigeria, Pakistan, Papua New Guinea, Philippines, S o Tom and Principe, Senegal, Solomon Islands, Sri Lanka, Sudan, Timor-Leste, Tunisia, Ukraine, Uzbekistan, Vanuatu, Vietnam, West Bank and Gaza, Zambia and ZimbabweAdditional IDA eligible: Dominica, Fiji, Grenada, Guyana, Kosovo, Maldives, Marshall Islands, Samoa, St. Lucia, St. Vincent and the Grenadines, Tonga and Tuvalu.
About Gavi, the Vaccine Alliance
Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate half the world s children against some of the world s deadliest diseases. Since its inception in 2000, Gavi has helped to immunise a whole generation over 760 million children and prevented more than 13 million deaths, helping to halve child mortality in 73 developing countries. Gavi also plays a key role in improving global health security by supporting health systems as well as funding global stockpiles for Ebola, cholera, meningitis and yellow fever vaccines. After two decades of progress, Gavi is now focused on protecting the next generation reaching the unvaccinated children still being left behind, employing innovative finance and the latest technology from drones to biometrics to save millions more lives, prevent outbreaks before they can spread and help countries on the road to self-sufficiency. Learn more at www.gavi.org and connect with us on Facebook Twitter.
The Vaccine Alliance brings together developing country and donor governments, the World Health Organization, UNICEF, the World Bank, the vaccine industry, technical agencies, civil society, the Bill Melinda Gates Foundation and other private sector partners. View the full list of donor governments and other leading organizations that fund Gavi s work here.
About CEPI
CEPI is an innovative partnership between public, private, philanthropic, and civil organisations, launched at Davos in 2017, to develop vaccines to stop future epidemics. CEPI has moved with great urgency and in coordination with WHO in response to the emergence of COVID-19. CEPI has initiated nine partnerships to develop vaccines against the novel coronavirus. The programmes are leveraging rapid response platforms already supported by CEPI as well as new partnerships.
Before the emergence of COVID-19, CEPI s priority diseases included Ebola virus, Lassa virus, Middle East Respiratory Syndrome coronavirus, Nipah virus, Rift Valley Fever and Chikungunya virus. CEPI also invested in platform technologies that can be used for rapid vaccine and immunoprophylactic development against unknown pathogens (Disease X).
About WHO
The World Health Organization provides global leadership in public health within the United Nations system. Founded in 1948, WHO works with 194 Member States, across six regions and from more than 150 offices, to promote health, keep the world safe and serve the vulnerable. Our goal for 2019-2023 is to ensure that a billion more people have universal health coverage, to protect a billion more people from health emergencies, and provide a further billion people with better health and wellbeing.
For updates on COVID-19 and public health advice to protect yourself from coronavirus, visit www.who.int and follow WHO on Twitter, Facebook, Instagram, LinkedIn, TikTok, Pinterest, Snapchat, YouTube

Read on the original site






WHO
World Mental Health Day: an opportunity to kick-start a massive scale-up in investment in mental health
WHO Information Notice for Users of In Vitro Diagnostics 2020/4
172 countries and multiple candidate vaccines engaged in COVID-19 vaccine Global Access Facility
Study provides comprehensive view of terrestrial venomous snakes and snakebite in the Middle East
World Hepatitis Day: fast-tracking the elimination of hepatitis B among mothers and children
Cervical Cancer Elimination Initiative Updates
Addressing the crisis in antibiotic development
The World Health Organization reminds public to remain vigilant through Mr Bean’s Essential COVID-19 Checklist
Countries failing to prevent violence against children, agencies warn
First rituximab similar biotherapeutic products prequalified
The value of integrating HIV prevention and contraceptive services
Statement from Dr Mike Ryan, Executive Director, WHO Health Emergencies Programme at the Yemen High-level Pledging Conference
Maintaining essential health services: new operational guidance for the COVID-19 context
Basic Psychosocial Skills: A Guide for COVID-19 Responders
FIFA, European Commission and World Health Organization launch #SafeHome campaign to support those at risk from domestic violence
Historic health assembly ends with global commitment to COVID-19 response
Meeting of the Global Network of WHO Collaborating Centres for Bioethics
WHO and International Olympic Committee team up to improve health through sport
WHO and Costa Rica preview technology pooling initiative to ensure access to COVID-19 health products for all
Online Survey for Health Professionals on a Healthy Recovery from COVID-19
WHO News
WHO and UNICEF recommit to accelerating health and well-being at all ages
WHO validates Myanmar for eliminating trachoma as a public health problem
Keep health workers safe to keep patients safe: WHO
Launch of the 2020 Global Action Plan for Healthy Lives and Well-being for All progress report
Join Us: Official UN General Assembly Side Event on progress and multisectoral action to End TB
WHO’s three messages for UN75
GDG Virtual Meeting on the update of the Consolidated Guidelines for use of antiretrovirals for preventing and treating HIV infection
Statement from the first ACT-Accelerator Facilitation Council meeting
Coronavirus Global Response: Access to COVID-19 Tools-Accelerator Facilitation Council holds inaugural meeting
More than 3 billion people protected from harmful trans fat in their food
WHO calls for global action on sepsis - cause of 1 in 5 deaths worldwide
Every woman’s right to a companion of choice during childbirth
COVID-19 could reverse decades of progress toward eliminating preventable child deaths, agencies warn
Leprosy: countries should step-up prevention initiatives to stimulate sluggish decline in new cases
Dengue control: three-year Indonesia trial shows promising results
Malaria and COVID-19: country perspectives
Ending Preventable Maternal Mortality online consultation for coverage targets for Ending Preventable Maternal Mortality
WHO convenes expert group for behaviour change
Letter to malaria partners (September 2020)
New research helps to increase understanding of the impact of COVID-19 for pregnant women and their babies
RT
Trump targeted with package containing deadly RICIN poison, intercepted by law enforcement — report
It s not the last one I ll break : Angry Djokovic smashes racket at Italian Open just weeks after US Open disqualification
Unbelievable : MMA fighter ends all-Russian scrap with BRUTAL UPKICK to send stunned opponent face-first onto the canvas (VIDEO)
Belarusian police arrest more than 100 people at women’s march in Minsk (VIDEOS)
Pirlo would be proud : Messi shows he’s still fired up at Barcelona with STUNNING pass in pre-season win (VIDEO)
‘Open interference’: Belarus warns against inclusion of opposition figure Tikhanovskaya in meeting of EU foreign ministers
Lockdown-defying Professor Neil Ferguson says UK needs… a SECOND LOCKDOWN
Republicans and Democrats swallow their past words as RBG replacement battle kicks off
Tour de France: Prodigy Pogacar set to become youngest champ in 110 YEARS as he earns shock win in showdown of Slovenians (VIDEO)
Thousands protest in Thailand demanding new government monarchy reform (VIDEOS)
Bale s back: Gareth Bale ends Real Madrid exile by returning to Premier League with former club Tottenham on loan
Two asteroids set to cross Earth’s orbit just hours apart as another Great Pyramid-sized space rock barrels our way
That looks consensual ? Aussie rules players warned over light-hearted bum-grab during game
The world has thousands of Covid-19 strains, but 99% of all Russian cases come from just two, says health watchdog
So much potential : Liverpool confirm £41 million capture of Wolves winger Diogo Jota
Too sexy for Instagram : Aussie surf sisters defy critics to launch XXX-rated websites (PHOTOS/VIDEOS))
With Russia ahead of the US in the hypersonic weapons race, Trump accuses Moscow of stealing American tech
Police arrest 11 as wildfires clear and rioting resumes in Portland (VIDEOS)
Is Iran into CHOPPING OFF ‘teen thieves’ fingers? Not quite, say local officials as MSM runs shocking headlines
Latvian doctor boasts to magazine he refused to help hospital visitor who spoke Russian